logo
Plus   Neg
Share
Email

Eli Lilly: FDA Grants Fast Track Designation To Empagliflozin - Quick Facts

Boehringer Ingelheim and Eli Lilly and Company (LLY) said the FDA has granted Fast Track designation to empagliflozin for the ongoing EMPEROR program, which will evaluate the effect of the tablet on cardiovascular death and hospitalization for heart failure in adults with chronic heart failure with reduced or preserved ejection fraction. The EMPEROR phase III studies are part of the empagliflozin chronic heart failure program.

Empagliflozin is marketed as Jardiance in the U.S. Jardiance is a registered trademark of Boehringer Ingelheim.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration has granted accelerated approval to Tazverik for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Epithelioid sarcoma is a rare sub-type of soft... STIHL recalls about 16,400 STIHL RE 90 pressure washers due to injury hazard. According to the company, the recalled pressure washer nozzle can disconnect from the spray wand when under pressure during use, posing an injury hazard. STIHL said it received seven reports of the nozzle detaching from... CVS Health Corp. launched 13 new HealthHUB locations in CVS Pharmacy stores across Philadelphia and South New Jersey. The healthcare company said it developed the HealthHUB store format to help people manage chronic conditions more conveniently and affordably. The store also features health and wellness products, clinical services and expertise.
Follow RTT
>